912 results on '"Linch, D."'
Search Results
2. Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes
3. Correction: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways
4. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
5. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
6. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
7. P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
8. P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS
9. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM
11. An Alternative Transcript of the Human GM-CSF Receptor Alpha Chain Lacking the Signal Sequence Is Found in AML Blasts and Normal Controls
12. The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3–5) yields an excellent outcome: A phase 2 UK NCRI/Bloodwise Trial (LLR 04058): 209
13. Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3–5) yields a good outcome without transplantation: A phase 2 UK NCRI/Bloodwise Trial: 210
14. Preclinical investigation and validation of a second generation CD19 directed chimeric antigen receptor (CAR), to target diffuse large B-cell lymphoma (DLBCL) for use in a phase 1 clinical trial: 186
15. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
16. Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals
17. Correction: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways
18. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia
19. A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma
20. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial
21. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
22. UK NCRI R-CHOP 14 v 21: study update: 35
23. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis
24. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
25. Allogeneic transplantation for hepatosplenic αβ T-cell lymphoma
26. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways
27. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation
28. Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies
29. Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial: 42
30. The impact of mutant level on clinical outcome in acute myeloid leukaemia differs according to the mutated gene: 44
31. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) trial: 26
32. First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007: 30
33. The outcome for elderly patients with diffuse large B cell lymphoma achieving partial response or relapsing at least a year after first-line therapy warrants consideration of aggressive salvage: 45
34. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning: 42
35. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukaemia is dependent on FLT3/ITD status: 34
36. Favourable outcome for allogeneic haematopoietic transplant recipients requiring intensive therapy unit admission with improved survival following reduced intensity conditioning: 105
37. Favourable outcome for haematopoietic transplant recipients requiring intensive therapy unit admission: a 10-year single-centre experience: O174
38. Imprecision of counting CFU-GM colonies and CD34-expressing cells
39. The theoretical basis of chemotherapy for hematological maliganancy
40. Favourable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins lymphoma: 328
41. Excellent long-term survival following reduced intensity allogeneic transplantation for multiply relapsed follicular lymphoma: 323
42. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia
43. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue
44. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
45. Primary sciatic nerve lymphoma: a case report and review of the literature
46. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK
47. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma
48. 15. Clinical Results in Lymphoma II: 074 CHLORAMBUCIL VERSUS OBSERVATION AFTER ANTI-HELICOBACTER THERAPY IN LOW-GRADE GASTRIC LYMPHOMA: RESULTS OF THE INTERNATIONAL LY03 TRIAL
49. Go6976, a novel and potent inhibitor of JAK2 and JAK3, reduces constitutive STAT activity and induces apoptosis in myeloid leukaemia and anaplastic lymphoma cells: 121
50. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.